Persons with dispensed medicines; origin
| Sex | Age | Origin | Medicine group (ATC) | Periods | Persons with medicines, relative (%) | Defined daily doses (DDD), relative (number per 1 000 persons) |
|---|---|---|---|---|---|---|
| Total male and female | 0 to 64 years, standardised | Origin: total | Total | 2020* | 56.54 | 290 |
| Total male and female | 0 to 64 years, standardised | Origin: total | Total | 2021* | 57.08 | 291 |
| Total male and female | 0 to 64 years, standardised | Origin: total | C Cardiovascular system | 2020* | 10.60 | 66 |
| Total male and female | 0 to 64 years, standardised | Origin: total | C Cardiovascular system | 2021* | 10.62 | 66 |
| Total male and female | 0 to 64 years, standardised | Origin: born in the Netherlands | Total | 2020* | 57.92 | 288 |
| Total male and female | 0 to 64 years, standardised | Origin: born in the Netherlands | Total | 2021* | 58.56 | 290 |
| Total male and female | 0 to 64 years, standardised | Origin: born in the Netherlands | C Cardiovascular system | 2020* | 10.46 | 65 |
| Total male and female | 0 to 64 years, standardised | Origin: born in the Netherlands | C Cardiovascular system | 2021* | 10.48 | 65 |
| Total male and female | 0 to 64 years, standardised | Origin: born in NL, parents in NL | Total | 2020* | 57.60 | 285 |
| Total male and female | 0 to 64 years, standardised | Origin: born in NL, parents in NL | Total | 2021* | 58.14 | 287 |
| Total male and female | 0 to 64 years, standardised | Origin: born in NL, parents in NL | C Cardiovascular system | 2020* | 10.47 | 65 |
| Total male and female | 0 to 64 years, standardised | Origin: born in NL, parents in NL | C Cardiovascular system | 2021* | 10.49 | 65 |
| Total male and female | 0 to 64 years, standardised | Origin: born in NL, parent(s) outside NL | Total | 2020* | 59.47 | 304 |
| Total male and female | 0 to 64 years, standardised | Origin: born in NL, parent(s) outside NL | Total | 2021* | 60.46 | 306 |
| Total male and female | 0 to 64 years, standardised | Origin: born in NL, parent(s) outside NL | C Cardiovascular system | 2020* | 10.26 | 64 |
| Total male and female | 0 to 64 years, standardised | Origin: born in NL, parent(s) outside NL | C Cardiovascular system | 2021* | 10.33 | 65 |
| Total male and female | 0 to 64 years, standardised | Origin: born in NL, 1 parent born in NL | Total | 2020* | 58.08 | 290 |
| Total male and female | 0 to 64 years, standardised | Origin: born in NL, 1 parent born in NL | Total | 2021* | 58.80 | 292 |
| Total male and female | 0 to 64 years, standardised | Origin: born in NL, 1 parent born in NL | C Cardiovascular system | 2020* | 10.02 | 62 |
| Total male and female | 0 to 64 years, standardised | Origin: born in NL, 1 parent born in NL | C Cardiovascular system | 2021* | 10.05 | 62 |
| Total male and female | 0 to 64 years, standardised | Origin: born in NL, parents born abroad | Total | 2020* | 60.83 | 324 |
| Total male and female | 0 to 64 years, standardised | Origin: born in NL, parents born abroad | Total | 2021* | 62.06 | 328 |
| Total male and female | 0 to 64 years, standardised | Origin: born in NL, parents born abroad | C Cardiovascular system | 2020* | 10.81 | 71 |
| Total male and female | 0 to 64 years, standardised | Origin: born in NL, parents born abroad | C Cardiovascular system | 2021* | 10.95 | 72 |
| Total male and female | 0 to 64 years, standardised | Origin: born outside the Netherlands | Total | 2020* | 48.42 | 306 |
| Total male and female | 0 to 64 years, standardised | Origin: born outside the Netherlands | Total | 2021* | 48.67 | 305 |
| Total male and female | 0 to 64 years, standardised | Origin: born outside the Netherlands | C Cardiovascular system | 2020* | 11.35 | 75 |
| Total male and female | 0 to 64 years, standardised | Origin: born outside the Netherlands | C Cardiovascular system | 2021* | 11.37 | 75 |
| Total male and female | 0 to 64 years, standardised | Origin country: The Netherlands | Total | 2020* | 57.60 | 285 |
| Total male and female | 0 to 64 years, standardised | Origin country: The Netherlands | Total | 2021* | 58.14 | 287 |
| Total male and female | 0 to 64 years, standardised | Origin country: The Netherlands | C Cardiovascular system | 2020* | 10.47 | 65 |
| Total male and female | 0 to 64 years, standardised | Origin country: The Netherlands | C Cardiovascular system | 2021* | 10.49 | 65 |
| Total male and female | 0 to 64 years, standardised | Origin country: Europe (excl. NL) | Total | 2020* | 46.00 | 223 |
| Total male and female | 0 to 64 years, standardised | Origin country: Europe (excl. NL) | Total | 2021* | 46.46 | 222 |
| Total male and female | 0 to 64 years, standardised | Origin country: Europe (excl. NL) | C Cardiovascular system | 2020* | 9.04 | 57 |
| Total male and female | 0 to 64 years, standardised | Origin country: Europe (excl. NL) | C Cardiovascular system | 2021* | 9.02 | 57 |
| Total male and female | 0 to 64 years, standardised | Origin country: outside Europe | Total | 2020* | 58.33 | 356 |
| Total male and female | 0 to 64 years, standardised | Origin country: outside Europe | Total | 2021* | 59.08 | 357 |
| Total male and female | 0 to 64 years, standardised | Origin country: outside Europe | C Cardiovascular system | 2020* | 12.07 | 78 |
| Total male and female | 0 to 64 years, standardised | Origin country: outside Europe | C Cardiovascular system | 2021* | 12.15 | 79 |
| Total male and female | 0 to 64 years, standardised | Origin country: Morocco | Total | 2020* | 65.33 | 422 |
| Total male and female | 0 to 64 years, standardised | Origin country: Morocco | Total | 2021* | 65.83 | 414 |
| Total male and female | 0 to 64 years, standardised | Origin country: Morocco | C Cardiovascular system | 2020* | 11.74 | 69 |
| Total male and female | 0 to 64 years, standardised | Origin country: Morocco | C Cardiovascular system | 2021* | 11.79 | 69 |
| Total male and female | 0 to 64 years, standardised | Origin country: Turkey | Total | 2020* | 65.38 | 474 |
| Total male and female | 0 to 64 years, standardised | Origin country: Turkey | Total | 2021* | 65.55 | 470 |
| Total male and female | 0 to 64 years, standardised | Origin country: Turkey | C Cardiovascular system | 2020* | 15.04 | 103 |
| Total male and female | 0 to 64 years, standardised | Origin country: Turkey | C Cardiovascular system | 2021* | 15.08 | 104 |
| Total male and female | 0 to 64 years, standardised | Origin country: Suriname | Total | 2020* | 63.83 | 483 |
| Total male and female | 0 to 64 years, standardised | Origin country: Suriname | Total | 2021* | 64.79 | 485 |
| Total male and female | 0 to 64 years, standardised | Origin country: Suriname | C Cardiovascular system | 2020* | 15.18 | 106 |
| Total male and female | 0 to 64 years, standardised | Origin country: Suriname | C Cardiovascular system | 2021* | 15.17 | 107 |
| Total male and female | 0 to 64 years, standardised | Origin country: Dutch Caribbean | Total | 2020* | 59.08 | 348 |
| Total male and female | 0 to 64 years, standardised | Origin country: Dutch Caribbean | Total | 2021* | 59.51 | 351 |
| Total male and female | 0 to 64 years, standardised | Origin country: Dutch Caribbean | C Cardiovascular system | 2020* | 12.48 | 85 |
| Total male and female | 0 to 64 years, standardised | Origin country: Dutch Caribbean | C Cardiovascular system | 2021* | 12.57 | 86 |
| Total male and female | 0 to 64 years, standardised | Origin country: Suriname | Total | 2020* | 53.63 | 271 |
| Total male and female | 0 to 64 years, standardised | Origin country: Suriname | Total | 2021* | 54.13 | 273 |
| Total male and female | 0 to 64 years, standardised | Origin country: Suriname | C Cardiovascular system | 2020* | 9.83 | 63 |
| Total male and female | 0 to 64 years, standardised | Origin country: Suriname | C Cardiovascular system | 2021* | 9.93 | 64 |
| Total male and female | 0 to 64 years, standardised | Origin country: outside Europe (exc. 5.. | Total | 2020* | 53.82 | 299 |
| Total male and female | 0 to 64 years, standardised | Origin country: outside Europe (exc. 5.. | Total | 2021* | 54.92 | 302 |
| Total male and female | 0 to 64 years, standardised | Origin country: outside Europe (exc. 5.. | C Cardiovascular system | 2020* | 11.10 | 70 |
| Total male and female | 0 to 64 years, standardised | Origin country: outside Europe (exc. 5.. | C Cardiovascular system | 2021* | 11.21 | 70 |
| Source: CBS. | ||||||
Table description
This table contains figures on the absolute number of persons to whom in the year concerned medicines were dispensed for which the costs are reimbursed under the statutory basic medical insurance. Also, the number of dispensed defined daily doses (DDDs) are presented. The figures are also expressed as a percentage of the total population in the category concerned. The population includes everybody registered in the Basic Registration of Persons (BRP) and living in the Netherlands at some point in the year concerned. Until 2010 the figures also included medicines dispensed to persons registered in the BRP, but no longer resident in the Netherlands.
Medicines provided to persons in hospitals and nursing homes are not included; medicines provided in residential homes for the elderly are included.
Data are broken down by medicine group, origin, age and sex.
Data available from 2020.
Status of the figures:
All figures are provisional.
Changes as of 14 December, 2022:
This is a new table due to the introduction of the new classification of population by origin. This table is the follow-up of the table 'Persons with dispensed medicines; background; 2006-2020'. See also section 3.
When will new figures be published?
New figures will be published in the last quarter of 2023.
Description topics
- Persons with medicines, relative
- Number of persons to whom medicines are dispensed in the year concerned that are reimbursed under the statutory basic medical insurance, expressed as a percentage of the total population of the category concerned registered in the Basic Registration of Persons (BRP) in that year.
- Defined daily doses (DDD), relative
- Defined Daily Dose (DDD) is de door de WHO vastgestelde gemiddelde dagelijkse dosis van een geneesmiddel, wanneer het geneesmiddel wordt ingezet voor de hoofdindicatie, bij een onderhoudsbehandeling voor volwassenen. Deze definitie maakt het mogelijk om het gebruik van verschillende toedieningsvormen en verschillende middelen met elkaar te vergelijken.
WHO: World Health Organisation, Wereldgezondheidsorganisatie